- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TAS-OX for Refractory Metastatic Colon Cancer (clinicaltrials.gov) - Mar 2, 2020 P1/2, N=68, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2019 --> Jul 2020
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TAS102 in Combination With NAL-IRI in Advanced GI Cancers (clinicaltrials.gov) - Jan 31, 2020 P1/2, N=64, Recruiting, We hope you will join us for this engaging event. Trial completion date: Feb 2021 --> Nov 2022 | Trial primary completion date: Feb 2021 --> Nov 2021
- |||||||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Journal: The toxicity profile of TAS-102. Practical considerations about neutropenia. (Pubmed Central) - Jan 29, 2020 Albeit generally well tolerated, clinically relevant neutropenia may interfere with the regular delivery of full-dose cycles with a possible detrimental effect on the dose-intensity. Judicious and personalized use of colony-stimulating growth factors as well as alterative schedules of drug delivery could mitigate neutropenia, so contributing to an even better therapeutic index of the drug.
- |||||||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Clinical, Journal: The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. (Pubmed Central) - Jan 28, 2020 Trifluridine-tipiracil is a new treatment option for patients with mCRC who have received at least 2 prior lines of standard chemotherapy (including fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and an antiepidermal growth factor receptor antibody in patients with KRAS wild-type tumors). Ongoing trials are investigating trifluridine/tipiracil in combination with other anticancer agents for mCRC and its use in other malignancies, such as metastatic gastric cancer.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date, Metastases: Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2020
P2, N=96, Completed, Ongoing trials are investigating trifluridine/tipiracil in combination with other anticancer agents for mCRC and its use in other malignancies, such as metastatic gastric cancer. Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Aug 2019 | Trial primary completion date: Oct 2022 --> Aug 2019
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Mekinist (trametinib) / Novartis, BeiGene
Trial completion date, Trial primary completion date, Combination therapy, Surgery, Metastases: Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 22, 2020 P1, N=26, Recruiting, Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Aug 2019 | Trial primary completion date: Oct 2022 --> Aug 2019 Trial completion date: Dec 2019 --> Sep 2020 | Trial primary completion date: Dec 2019 --> Sep 2020
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, Metastases: A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (clinicaltrials.gov) - Jan 21, 2020 P1, N=48, Active, not recruiting, Trial completion date: Dec 2019 --> Sep 2020 | Trial primary completion date: Dec 2019 --> Sep 2020 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open: TAS-102 NEC: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (clinicaltrials.gov) - Jan 18, 2020 P2, N=14, Recruiting, Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Not yet recruiting --> Recruiting
- |||||||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Clinical, Observational data, Review, Journal: A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. (Pubmed Central) - Jan 2, 2020 A Japanese phase II trial and two phase III trials, RECOURSE and TERRA, demonstrated that FTD/TPI prolonged overall survival. What this study adds This systematic review and meta-analysis of real life data from 64 sites indicates that the effectiveness in daily clinical practice settings of FTD/TPI monotherapy in late stage mCRC reflects the outcomes in RECOURCE but is inferior to the outcomes in the Japanese phase II trial and TERRA.
- |||||||||| paclitaxel / Generic mfg.
Clinical, Journal: Review: Gastric cancer-Clinical aspects. (Pubmed Central) - Jan 2, 2020 In a systematic investigation conducted on Chinese patients with GC, CLDN18-ARHGAP26/6 fusion was associated with signet-ring cell content and was prognostic for a worse outcome and predictive for no benefit from oxaliplatin/fluoropyrimidine-based chemotherapy. Organoid cultures represent an appealing model that may be applied for therapy response testing in the near future.
- |||||||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO). (Level 1, West Hall - Poster Board N9) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1023; P1 This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Taiho Oncology, Inc. Research Funding: This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Taiho Oncology, Inc
|